TUMOR MARKERS AS A DIAGNOSTIC KEY FOR HILAR CHOLANGIOCARCINOMA

Objective: Hilar cholangiocarcinoma is the fourth most common gastrointestinal malignancy. CA19-9 and CEA are helpful devices in the management of gastrointestinal malignancies and belong to clinical routine in surgical oncology. But the validity of these parameters in terms of tumor extension and prognosis of bile duct malignancies still remains unclear. Methods: From 1998 to 2008, we obtained preoperative CA19-9 and CEA serum levels in 136 patients with hilar cholangiocarcinoma. We correlated tumor stage, resectability rate and survival with preoperative CA19-9 and CEA serum levels. Results: CA19-9 (UICC I: 253 +/- 561U/ml; UICC II: 742 +/- 1572 U/ml; UICC III: 906 +/- 1708 U/ml; UICC IV: 1707 +/- 3053U/ml) and CEA levels (UICC I: 2.9 +/- 3.81//ml; UICC II: 4.6 +/- 6.5 U/ml; UICC III: 18.1 +/- 29.6 U/ml; UICC IV: 22.7 +/- 53.9 U/ml) increase significantly with rising tumor stage. Patients with preoperative serum levels of CA19-9 (>1000U/ml) and CEA (>14.4ng/ml) showed a significant poorer resectability rate and survival than patients with lower CA19-9 and CEA serum levels respectively. Conclusion: CA19-9 and CEA serum levels are associated with the tumor stage. If preoperatively obtained CA19-9 and CEA serum levels are highly elevated patients have an even worse survival and the frequency of irresectability is significantly higher.